Yes OK The World Health Organization (WHO) recommended the use of the AstraZeneca and Oxford vaccine against coronavirus for people over 65 years of age, some European countries still question the application of this inoculant in that age group, claiming that there is insufficient data on the effectiveness of the trial. In Argentina, it is not planned to modify the vaccination campaign, say the experts consulted on this issue
“In our country, The COVID-19 AstraZeneca vaccine was authorized as a product for emergency use on December 30 by the Anmat. It can be administered in people over 60 years of age, because the WHO recommendation was followed based on evidence that shows that the vaccine has a safe profile ”, the doctor told Infobae Ángela Gentile, member of the National Commission for Vaccine Safety of Argentina.
The expert added that Europe’s regulatory agency, The EMEA has not yet authorized it for those over 60 years old because it is waiting for more additional data, but it is very likely that soon it will authorize the use.
For his part, the infectious disease doctor and epidemiologist Hugo Pizzi, tenured professor at the National University of Córdoba, he assured this medium: “Here, we follow through with the manufacturer’s regulations. In fact, I am in Ciudad Universitaria and he is vaccinated with it at a dizzying rate”, Shared Infobae.
According to Roberto Debbag, vice president of the Latin American Society of Pediatric Infectology, “Recently, the efficacy of this drug was published in Scotland; some countries are reviewing and possibly starting to approve it, as is the case of Germany, which has already announced that it is open to using the vaccine in people over 60 years of age ”.
The advance in Scotland
Few days ago, AstraZeneca, the British-born pharmaceutical company with operations in more than 100 countries, released the publication of preliminary results of a study from the Scottish public health service that estimates the effectiveness of the first doses of vaccination, obtained after inoculating just over 1.13 million people (35% of the population) over 18 years of age, most of them being adults over 65 years of age.
According to this report, AstraZeneca vaccine reduces coronavirus hospitalization by 94% in 28-34 days after vaccination. Likewise, when analyzing the combined effectiveness with different vaccines, similar results were obtained in all age groups, including people aged 80 years and over.
These data help reinforce the results obtained in the combined analysis of clinical trials conducted in the United Kingdom, Brazil and South Africa, in which there were no cases of hospitalization or serious illness due to COVID-19, after 22 days of administration. of the AstraZeneca vaccine.
The efficacy of the vaccine was 59.5% in those participants who received the two recommended doses with an interval between doses of four to 12 weeks.
Results of a combined analysis of phase 2 and phase 3 clinical trials in the UK, Brazil and South Africa published on February 19 in The Lancet realize that, After the first dose, a vaccine efficacy of 76% is shown, maintaining protection until the second dose.. Efficacy after the second dose increases up to 82% when the second dose is given with an interval between doses of 12 weeks or more.
Already at the beginning of February, and attentive to the doubts that have arisen in countries such as Belgium, Austria, Denmark, Germany and Norway, among other nations of the Old Continent, which had announced that they would not apply the vaccine to their population over 65 years of age, WHO endorsed the emergency use of this inoculant against the coronavirus for “all people over 18 years of age with no upper age limit”.
I KEEP READING: